These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 17548227)

  • 1. Cancer therapy: new drugs are emerging based on molecular targeting but still many challenges.
    Altucci L; Balducci L; Irminger-Finger I
    Int J Biochem Cell Biol; 2007; 39(7-8):1278-9. PubMed ID: 17548227
    [No Abstract]   [Full Text] [Related]  

  • 2. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway.
    Wang S
    Oncogene; 2008 Oct; 27(48):6207-15. PubMed ID: 18931688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TRAIL as a target in anti-cancer therapy.
    Wu GS
    Cancer Lett; 2009 Nov; 285(1):1-5. PubMed ID: 19299078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Molecular treatment of cancer. Imatinib].
    Lopez M
    Clin Ter; 2001; 152(6):399-407. PubMed ID: 11865537
    [No Abstract]   [Full Text] [Related]  

  • 5. TNF-related apoptosis-inducing ligand: signalling of a 'smart' molecule.
    Manzo F; Nebbioso A; Miceli M; Conte M; De Bellis F; Carafa V; Franci G; Tambaro FP; Altucci L
    Int J Biochem Cell Biol; 2009 Mar; 41(3):460-6. PubMed ID: 18243765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The TRAIL apoptotic pathway in cancer onset, progression and therapy.
    Johnstone RW; Frew AJ; Smyth MJ
    Nat Rev Cancer; 2008 Oct; 8(10):782-98. PubMed ID: 18813321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On the offensive.
    Abbott A
    Nature; 2002 Apr; 416(6880):470-4. PubMed ID: 11932714
    [No Abstract]   [Full Text] [Related]  

  • 8. Advances in molecular targets and cancer therapeutics.
    Westwell AD
    Drug Discov Today; 2004 Mar; 9(5):207-9. PubMed ID: 14980538
    [No Abstract]   [Full Text] [Related]  

  • 9. Progressive thoughts about progressive disease.
    Shah NP
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5229-31. PubMed ID: 17875748
    [No Abstract]   [Full Text] [Related]  

  • 10. EORTC-NCI-AACR - 18th Symposium - Molecular Targets and Cancer Therapeutics. Pediatric drugs, biomarkers and new therapies.
    Kibble A
    IDrugs; 2007 Jan; 10(1):5-7. PubMed ID: 17187303
    [No Abstract]   [Full Text] [Related]  

  • 11. [Pharmazie in unserer Zeit 5/2008].
    Dingermann T; Laufer S; Winckler T
    Pharm Unserer Zeit; 2008; 37(5):349. PubMed ID: 18729281
    [No Abstract]   [Full Text] [Related]  

  • 12. [Targeted anticancer drugs and their development].
    Kervinen J; Gahmberg CG
    Duodecim; 2004; 120(19):2323-30. PubMed ID: 15565985
    [No Abstract]   [Full Text] [Related]  

  • 13. Telomerase inhibition combined with other chemotherapeutic reagents to enhance anti-cancer effect.
    Tauchi T; Ohyashiki JH; Ohyashiki K
    Methods Mol Biol; 2007; 405():181-9. PubMed ID: 18369825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL).
    Ashkenazi A; Holland P; Eckhardt SG
    J Clin Oncol; 2008 Jul; 26(21):3621-30. PubMed ID: 18640940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unexplored pharmacokinetic opportunities with microdosing in oncology.
    Sparreboom A
    Clin Cancer Res; 2007 Jul; 13(14):4033-4. PubMed ID: 17634525
    [No Abstract]   [Full Text] [Related]  

  • 16. EORTC-NCI-AACR - 18th Symposium - Molecular Targets and Cancer Therapeutics.
    Kibble A
    IDrugs; 2007 Jan; 10(1):1-2. PubMed ID: 17187301
    [No Abstract]   [Full Text] [Related]  

  • 17. Emerging drugs in the treatment of pancreatic cancer.
    Mahalingam D; Kelly KR; Swords RT; Carew J; Nawrocki ST; Giles FJ
    Expert Opin Emerg Drugs; 2009 Jun; 14(2):311-28. PubMed ID: 19466902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by dimethyl-celecoxib in human non small-cell lung cancer cells.
    Chen S; Liu X; Yue P; Schönthal AH; Khuri FR; Sun SY
    Mol Pharmacol; 2007 Nov; 72(5):1269-79. PubMed ID: 17684158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is TRAIL the holy grail of cancer therapy?
    Newsom-Davis T; Prieske S; Walczak H
    Apoptosis; 2009 Apr; 14(4):607-23. PubMed ID: 19194800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies on search for bioactive natural products targeting TRAIL signaling leading to tumor cell apoptosis.
    Ishibashi M; Ohtsuki T
    Med Res Rev; 2008 Sep; 28(5):688-714. PubMed ID: 18273883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.